NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

• ClinicalTrials.gov Identifier: NCT01098266
• Recruitment Status: Completed
• First Posted: April 2, 2010
• Results First Posted: September 17, 2019
• Last Update Posted: September 17, 2019
• Sponsor: AGC Biologics S.p.A.
• Information provided by (Responsible Party): AGC Biologics S.p.A.

Tracking Information

• First Submitted Date: March 17, 2010
• First Posted Date: April 2, 2010
• Results First Submitted Date: June 5, 2019
• Results First Posted Date: September 17, 2019
• Last Update Posted Date: September 17, 2019
• Actual Study Start Date: April 12, 2010
• Actual Primary Completion Date: April 29, 2014 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: August 28, 2019)

Overall Survival (OS) [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, wichever came first, assesed up to 48 months ]

Defined as the time from the date of randomization until the date of death due to any cause or the last date the patient was known to be alive

Original Primary Outcome Measures (submitted: April 1, 2010)

Overall Survival (OS) [ Time Frame: every 6-12 weeks ]

Defined as the time from the date of randomization until the date of death due to any cause or the last date the patient was known to be alive

Current Secondary Outcome Measures (submitted: August 28, 2019)

• Progression-Free Survival (PFS) [ Time Frame: From the date of randomization until the date of first documented progression or date of death from any cause, wichever came first, assessed up to 48 months ]
  Defined as the time from the date of randomization until disease progression, or deathdue to any couse or the last patient was konwn to be alive. Progression is defined usind Response Evaluation Criteria In Solid Tumors Criteria (Recist v1.1), as a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition torelative increase of 20% the sum must also demonstrate an absolute increase of at least 5 mm. In addition the appearance of one or more new lesions was also considered progression
• Disease Control Rate (DCR) [ Time Frame: Assessed every 6-12 weeks, up to 100 weeks ]
  Disease control rate (DCR), defined as the percentage of patients who have a best-response rating of complete or partial response or stable disease, according to MPM-modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria
• Number of Partecipants With Disease Control for ≥ 6 Months [ Time Frame: Assessed every 6-12 weeks, up to 100 weeks ]
  Measured from the date of randomization until disease progression, or death due to any cause
• Number of Partecipants With Adverse Events [ Time Frame: Assessed every 6-12 weeks, up to 100 weeks ]
  All adverse events will be recorded according to CTC version 4.02 (CTC reference: http://ctep.cancer.gov/reporting/ctc.html) on the case report forms (CRFs); the investigator will decide if those events are drug related and his decision will be recorded on the forms for all adverse events.
• Time to LCSS Symptomatic Progression [ Time Frame: from the date of randomization to the date of the LCSS assessment on which symptomatic progression was identified, assessed on cycle 2, cycle 4 and cycle 6 (each cycle lasted 21 days) ]
  Quality of life (QoL) assessment was performed by using a questionnaire according to The Lung Cancer Symptom Scale (LCSS) . The LCSS is designed as a disease and site-specific measure of QoL particularly for use in clinical trials. It evaluates six major symptoms (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain) associated with lung malignancies and their effect on overall symptomatic distress, functional activities, and global QoL. Within this trial the questionnaire according to LCSS was only recorded by the patient (patient's scale). QoL assessment was performed by using a questionnaire according to LCSS, which consists of nine 100-mm visual analog scales, with scores reported from 0 to 100 (0 representing the best score). The LCSS subscore is the average symptom burden index computed as the mean score for all six major symptoms. Symptomatic progression was defined as a worsening in the average symptom burden index by 25%.
• Evaluation of Medical Care Utilization in the Two Treatment Arms [ Time Frame: Assessed every 6-12 weeks, up to 100 weeks ]
  Medical resource use data collected will be used in health economic analyses where it may be combined with other data from other sources such as cost data or other clinical parameters.

Original Secondary Outcome Measures (submitted: April 1, 2010)

• Progression-Free Survival (PFS) [ Time Frame: every 6-12 weeks ]
  Defined as the time from the date of randomization until disease progression, or death
• Disease Control Rate (DCR) [ Time Frame: every 6-12 weeks ]
  Defined as the percentage of patients who have a best-response rating of complete response, partial response, or stable disease
• Duration of Disease Control [ Time Frame: every 6-12 weeks ]
  Measured from the date of randomization until disease progression, or death due to any cause
• Safety and Toxicity according to NCI-CTCAE criteria (version 4.02) [ Time Frame: every 6-12 weeks ]
• Quality of life (QoL) according to Lung Cancer Symptom Scale [ Time Frame: every 6-12 weeks ]
• Evaluation of medical care utilization in the two treatment arms [ Time Frame: every 6-12 weeks ]
  Medical resource use data collected will be used in health economic analyses where it may be combined with other data from other sources such as cost data or other clinical parameters.

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
• Official Title: NGR015: Randomized Double-blind Phase III Study of NGR-hTNF Plus Best Investigator's Choice (BIC) Versus Placebo Plus BIC in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma (MPM)
• Brief Summary: The main objective of the trial is to document the efficacy of NGR-hTNF administered at low dose weekly in advanced Malignant Pleural Mesothelioma patients previously treated with a pemetrexed-based chemotherapy regimen.

Detailed Description

Currently, there are no regulatory-approved or widely accepted treatment options for patients failing a standard pemetrexed-based chemotherapy regimen.

For this reason, the best supportive care (BSC) alone might be considered as a standard reference for a randomized phase III trial in this setting.

However, single-agent chemotherapeutic agents (such as doxorubicin,gemcitabine, or vinorelbine) with a well-documented safety profile and antitumor activity are also used in clinical practice.

Therefore, the best investigator's choice (BIC) between either best supportive care alone or combined with a few selected single-agent chemotherapy (including doxorubicin, gemcitabine, or vinorelbine) might be considered as an acceptable reference arm as well in this setting.

The current phase III study aims to show a superior efficacy in terms of overall survival duration of NGR-hTNF 0.8 µg/mq weekly plus BIC versus placebo plus BIC in advanced MPM patients progressing after a standard pemetrexed-based chemotherapy.

• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment
• Condition: Malignant Pleural Mesothelioma

Intervention

• Drug: NGR-hTNF plus Best Investigator's Choice (BIC)
  • NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.
  • Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis

  • Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:

    1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles
    2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles
    3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)
  Other Name: NGR-hTNF+BIC
• Drug: Placebo plus Best Investigator's Choice (BIC)
  • Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.
  • Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis

  • Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:

    1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles
    2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles
    3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)
  Other Name: Placebo+BIC

Study Arms

• Experimental: A: NGR-hTNF + BIC
  NGR-hTNF plus Best Investigator's Choice
  Intervention: Drug: NGR-hTNF plus Best Investigator's Choice (BIC)
• Placebo Comparator: B: Placebo+BIC
  Placebo plus Best Investigator's Choice
  Intervention: Drug: Placebo plus Best Investigator's Choice (BIC)

• Publications *: Gregorc V, Gaafar RM, Favaretto A, Grossi F, Jassem J, Polychronis A, Bidoli P, Tiseo M, Shah R, Taylor P, Novello S, Muzio A, Bearz A, Greillier L, Fontana F, Salini G, Lambiase A, O'Brien M. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2018 Jun;19(6):799-811. doi: 10.1016/S1470-2045(18)30193-1. Epub 2018 May 9.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: December 20, 2017): 400
• Original Estimated Enrollment (submitted: April 1, 2010): 390
• Actual Study Completion Date: December 2017
• Actual Primary Completion Date: April 29, 2014 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Age ≥ 18 years
• Histologically or cytological confirmed malignant pleural mesothelioma of any of the following subtype: epithelial, sarcomatoid, mixed, or unknown
• Prior treatment with no more than one systemic pemetrexed-based chemotherapy regimen administered for advanced or metastatic disease. Prior use of a biological agent in combination with a pemetrexed-based regimen and prior administration of intrapleural cytotoxic agents are allowed. Patients who have previously received anthracyclines should not receive doxorubicin
• ECOG Performance Status 0 - 2
• Life expectancy of ≥ 12 weeks

• Adequate baseline bone marrow, hepatic and renal function, defined as follows:

  1. Neutrophils ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L; hemoglobin ≥ 9 g/dL
  2. Bilirubin ≤ 1.5 x ULN
  3. AST and/or ALT ≤ 2.5 x ULN in absence of liver metastasis or ≤ 5 x ULN in presence of liver metastasis
  4. Serum creatinine < 1.5 x ULN
• Measurable or non-measurable disease according to MPM-modified RECIST criteria

• Patients may have had prior therapy providing the following conditions are met:

  1. Surgery: wash-out period of 14 days
  2. Systemic and radiation anti-tumor therapy: wash-out period of 28 days
• Patients must give written informed consent to participate in the study

Exclusion Criteria:

• Patients must not receive any other investigational agents while on study
• Patients with myocardial infarction within the last six months, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication
• Uncontrolled hypertension
• QTc interval (congenital or acquired) > 450 ms
• History or evidence upon physical examination of CNS disease unless adequately treated (e.g., primary brain tumor, any brain metastasis, seizure not controlled with standard medical therapy, or history of stroke)
• Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol
• Known hypersensitivity/allergic reaction to human albumin preparations or to any of the excipients
• Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol
• Pregnancy or lactation

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Belgium, Canada, Egypt, France, Ireland, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom, United States

Administrative Information

• NCT Number: NCT01098266
• Other Study ID Numbers: NGR015; 2009-016879-29 ( EudraCT Number )
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: AGC Biologics S.p.A.
• Original Responsible Party: MolMed
• Current Study Sponsor: AGC Biologics S.p.A.
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Antonio Lambiase, MD; AGC Biologics S.p.A.

• PRS Account: AGC Biologics S.p.A.
• Verification Date: August 2019